T. Ciuleanu

发表

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

G. Giaccone, F. Cappuzzo, T. Ciuleanu, 2010, The Lancet. Oncology.

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

J. Szustakowski, K. O'Byrne, S. Ramalingam, 2018, The New England journal of medicine.

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

N. Girard, J. Taube, S. Broderick, 2022, The New England journal of medicine.

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.

T. Ciuleanu, M. Rodríguez-Torres, I. Bondarenko, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Erlotinib in previously treated non-small-cell lung cancer.

Renato Martins, Andrea Bezjak, Dongsheng Tu, 2005, The New England journal of medicine.

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.

R. Ramlau, M. Krzakowski, A. Santoro, 2012, The Lancet. Oncology.

Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.

T. Ciuleanu, G. Fountzilas, K. Markou, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Access to Novel Drugs for Non‐Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis

J. Jassem, T. Ciuleanu, T. Čufer, 2019, The oncologist.

Access to Novel Drugs for Non‐Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis

J. Jassem, T. Ciuleanu, T. Čufer, 2019, The oncologist.

New Multimedia Platform for Improving Chemotherapy Prescription in Veterinary Patologic Oncology – A Marketing Study

Laura Elisabeta Ciuleanu, T. Ciuleanu, A. Pop, 2015 .

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

D. Carbone, E. Felip, T. John, 2021, ESMO open.

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

D. Carbone, E. Felip, L. Paz-Ares, 2021, The Lancet. Oncology.

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

E. Van Cutsem, F. Lordick, C. Punt, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

5-Fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells.

I. Berindan‐Neagoe, T. Ciuleanu, O. Bălăcescu, 2013, Journal of gastrointestinal and liver diseases : JGLD.

Report from the OECI Oncology Days 2014

P. Riegman, D. Razavi, T. Ciuleanu, 2014, Ecancermedicalscience.

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).

F. Khuri, R. Salgia, G. Shapiro, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.

T. Ciuleanu, B. Alekseev, S. Pal, 2022, European urology.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

E. Van Cutsem, J. Tabernero, Tae Won Kim, 2015, The Lancet. Oncology.

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study

E. Van Cutsem, J. Tabernero, A. Grothey, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial

E. Van Cutsem, J. Tabernero, V. Heinemann, 2017, Cancer Chemotherapy and Pharmacology.

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression†

E. Van Cutsem, J. Tabernero, T. Ciuleanu, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

BODY MASS INDEX AS A PROGNOSTIC FACTOR FOR DISEASE PROGRESSION IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH BEVACIZUMAB BASED SYSTEMIC THERAPY.

T. Ciuleanu, V. Nagy, C. Căinap, 2017, Acta endocrinologica.

Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients

T. Ciuleanu, J. Latz, J. Vermorken, 2009, Cancer Chemotherapy and Pharmacology.

Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer

M. Socinski, K. O'Byrne, T. Ciuleanu, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

T. Ciuleanu, N. Thatcher, M. O'Brien, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-157 Survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC

T. Ciuleanu, M. O'Brien, G. Ross, 2005 .

A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer.

K. Krejcy, T. Ciuleanu, A. Knuuttila, 2012, Lung cancer.

XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

U. Gatzemeier, T. Ciuleanu, M. Dediu, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC).

T. Ciuleanu, B. Basson, G. Teodorescu, 2005, Lung cancer.

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

T. Ciuleanu, M. Wojtukiewicz, C. Lebedinsky, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.

F. Cappuzzo, K. Syrigos, Michael Thomas, 2016, Lung cancer.

PL-3 Results of the randomized international adjuvant lung cancer trial (IALT): Cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (PTS) with resected non-small cell lung cancer (NSCLC)

J. Pignon, R. Pirker, T. Ciuleanu, 2003 .

A Case Report of EGFR-mutated Metastatic Lung Adenocarcinoma with Long-term Survival on Systemic Treatment

T. Ciuleanu, D. Iancu, Daniel Dulf, 2021, Journal of Medical and Radiation Oncology.

Randomized phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non–small cell lung cancer

Michael Thomas, Keunchil Park, T. Ciuleanu, 2016 .

Central and Eastern European Experience with Sunitinib in Metastatic Renal Cell Carcinoma: A Sub-analysis of the Global Expanded-Access Trial

T. Ciuleanu, J. Mardiak, E. Vrdoljak, 2015, Pathology & Oncology Research.

A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer

T. Ciuleanu, A. Croitoru, P. Koralewski, 2020, Oncotarget.

Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.

G. Scagliotti, P. Bunn, J. Denne, 2017, Lung cancer.

TC has received speaker's honoraria and payment for consultancy at advisory boards from Eli Lilly and F Hoff mann-La Roche.

T. Ciuleanu, 2012 .

Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC).

K. Krejcy, M. Krzakowski, J. Kim, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

K. Krejcy, Yi-long Wu, M. Krzakowski, 2009, The Lancet.

Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC).

K. Krejcy, M. Krzakowski, J. Kim, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.

D. Carbone, E. Felip, L. Paz-Ares, 2020 .

NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

M. Socinski, D. Carbone, S. Peters, 2016 .

A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea

T. Ciuleanu, J. Devane, M. Martín, 2013, British Journal of Cancer.

Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis

S. Pintea, T. Ciuleanu, Adina Nemeș, 2021, Experimental and therapeutic medicine.

A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC).

C. Schumann, M. Socinski, F. Hirsch, 2014 .

Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

S. Gettinger, Han Chang, T. Ciuleanu, 2018, Annals of Oncology.

Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases.

N. Pavlidis, T. Ciuleanu, G. Fountzilas, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Altered left ventricular diastolic performance in oncologic patients treated with epirubicin.

T. Ciuleanu, C. Duncea, D. Rădulescu, 2007, Congestive heart failure.

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

P. Murawa, M. Gore, C. Bokemeyer, 2010, International journal of cancer.

OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

H. Groen, L. Urban, E. Felip, 2019, Journal of Thoracic Oncology.

Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.

L. Urban, K. O'Byrne, Keunchil Park, 2021 .

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

Neuroendocrine tumor of gallbladder with liver and retroperitoneal metastases and a good response to the chemotherapeutical treatment

C. Iancu, A. Bartos, T. Ciuleanu, 2015, Journal of Medical Ultrasonics.

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.

L. Urban, K. O'Byrne, Keunchil Park, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study

A. Khorana, E. Gallardo, E. Macias, 2018, Journal of thrombosis and haemostasis : JTH.

O-163 Prevention of thromboembolic complications with the low-molecular-weight heparin certoparin in non-small-cell lung carcinoma (TOPIC-2)

U. Gatzemeier, T. Ciuleanu, P. Zatloukal, 2005 .

Tecemotide ( L-BLP 25 ) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer ( START ) : a randomised , double-blind , phase 3 trial

M. Socinski, F. Shepherd, R. Ramlau, 2013 .

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

M. Socinski, F. Shepherd, R. Ramlau, 2014, The Lancet. Oncology.

Extrahepatic Metastases of Hepatocellular Carcinoma : a Case Report

T. Ciuleanu, D. Iancu, A. Crăciunescu, 2015 .

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.

L. Seymour, K. Ding, F. Shepherd, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

E. Van Cutsem, F. Lordick, C. Punt, 2014 .

Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

F. Lordick, C. Punt, M. Ducreux, 2014 .

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Marc Peeters, Hua Yu, Gregory Wilson, 2015, Clinical Cancer Research.

FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC).

T. Ciuleanu, K. Kaczirek, T. Brodowicz, 2014 .

D04Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer

J. Tabernero, T. Ciuleanu, G. Bodoky, 2016 .

2123 Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer

J. Tabernero, T. Ciuleanu, G. Bodoky, 2015 .

1303PDNivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status

J. Jassem, L. Paz-Ares, T. Ciuleanu, 2017 .

Delay in time to worsening of symptoms (TWS) of advanced non-small cell lung cancer (NSCLC) using gemcitabine (gem) maintenance therapy.

R. Ramlau, M. Krzakowski, T. Ciuleanu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T. Ciuleanu, B. Alekseev, S. Pal, 2022, The oncologist.

Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.

N. Girard, K. O'Byrne, S. Ramalingam, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

M. Socinski, K. O'Byrne, T. Ciuleanu, 2008 .

Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary Dimitrios KrikelisGeorge PentheroudakisAnna GoussiaVassiliki Siozopoulou • Mattheos BobosDimitrios PetrakisAikaterini StoyianniVassilios Golfinopoulos • Andres CervantesTudor Ci

N. Pavlidis, T. Ciuleanu, G. Fountzilas, 2012 .

EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

R. Ferris, T. Ciuleanu, B. Keam, 2019, Journal of Clinical Oncology.

Prognostic value of paranasopharyngeal extension of nasopharyngeal carcinoma (NPC)

T. Ciuleanu, E. Ciuleanu, N. Todor, 1999 .

Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study.

T. Ciuleanu, E. Ciuleanu, N. Todor, 2008, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.

T. Ciuleanu, D. Radosavljevic, T. Brodowicz, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

E. Van Cutsem, F. Lordick, C. Punt, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and Evaluation of a Software-based Clinical Pharmacography System

N. Todor, Mihai Borzan, Laura Elisabeta Ciuleanu, 2015 .

First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer

M. Socinski, D. Carbone, S. Peters, 2017, The New England journal of medicine.

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer

T. Ciuleanu, O. Sorițău, M. Zdrenghea, 2021, OncoTargets and therapy.

Randomized phase II trial of irofulven (IROF)/prednisone (P), IROF/capecitabine (C)/P or mitoxantrone (M)/P in docetaxel-pretreated hormone refractory prostate cancer (HRPC) patients (pts).

J. Hainsworth, T. Ciuleanu, L. Hart, 2006, Journal of Clinical Oncology.

Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy

T. Ciuleanu, D. Cenariu, S. Pașca, 2021, Journal of cellular and molecular medicine.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

C. Schumann, M. Socinski, R. Kurek, 2015, The Lancet. Oncology.

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

N. Agarwal, C. Drake, H. Scher, 2014, The Lancet. Oncology.

A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous non-small cell lung cancer (sqNSCLC) previously treated with platinum-based chemotherapy.

G. Scagliotti, R. Govindan, I. Bondarenko, 2016 .

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

T. Ciuleanu, G. Bodoky, N. Tebbutt, 2012, Investigational New Drugs.

A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.

H. Groen, J. Milanowski, T. Ciuleanu, 2013, Lung cancer.

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.

R. Ferris, T. Ciuleanu, B. Keam, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.

W. Scheithauer, T. Ciuleanu, F. Wrba, 2010, World journal of gastroenterology.

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.

N. Agarwal, C. Drake, H. Scher, 2020, European urology.

Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group

N. Pavlidis, T. Ciuleanu, K. Papadopoulou, 2014, Clinical & Experimental Metastasis.

1450 POSTER Immunohistochemical Profiling of Signalling Pathways in Cancer of Unknown Primary (CUP)

N. Pavlidis, T. Ciuleanu, G. Pentheroudakis, 2011 .

Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

G. Scagliotti, M. Krzakowski, J. R. Pereira, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01).

R. Arriagada, C. Faivre-Finn, S. Senan, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.

R. Arriagada, C. Faivre-Finn, S. Senan, 2009, The Lancet. Oncology.

Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients

I. Berindan‐Neagoe, T. Ciuleanu, A. Eniu, 2022, International journal of environmental research and public health.

Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe

E. Giannoulatou, T. Ciuleanu, A. Psyrri, 2018, International journal of cancer.

Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials.

F. Cappuzzo, R. Osarogiagbon, T. Ciuleanu, 2015, Translational lung cancer research.

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

G. Giaccone, T. Ciuleanu, W. Brugger, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment Patterns and Real-world Evidence for Stage III Non-small Cell Lung Cancer in Central and Eastern Europe

T. Ciuleanu, M. Vrankar, M. Jakopović, 2020, Radiology and oncology.

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

R. McCormack, T. Ciuleanu, J. Douillard, 2013, British Journal of Cancer.

Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer

Michael Thomas, Keunchil Park, T. Ciuleanu, 2017, British Journal of Cancer.

Malignant primary pulmonary tumor with hemangiopericytoma-like features: conventional hemangiopericytoma versus solitary fibrous tumor.

T. Ciuleanu, S. Pripon, L. Radulescu, 2007, Clinical lung cancer.

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

T. Ciuleanu, L. Stelmakh, S. Cicėnas, 2012, The Lancet. Oncology.

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.

M. Socinski, F. Shepherd, R. Ramlau, 2013 .

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC

R. McCormack, T. Ciuleanu, J. Douillard, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Is there a correlation between peripheral blood expression of angiogenic transcriptional factors/receptors and colorectal cancer?

I. Berindan‐Neagoe, T. Ciuleanu, O. Bălăcescu, 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Introduction Is there a correlation between peripheral blood expression of angiogenic transcriptional factors / receptors and colorectal cancer ?

I. Berindan‐Neagoe, T. Ciuleanu, O. Bălăcescu, 2015 .

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Andreas Sashegyi, Michael Thomas, Federico Cappuzzo, 2014, The Lancet.

Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set

D. Mytelka, E. Van Cutsem, J. Tabernero, 2018, ESMO Open.

A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial

A. Bezjak, L. Seymour, S. Thongprasert, 2004 .

Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.

S. Gettinger, S. Peters, T. Ciuleanu, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial

P. Fishman, T. Ciuleanu, A. Croitoru, 2021, Cancers.

CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.

J. Milanowski, E. Felip, J. V. van Meerbeeck, 2020, European journal of cancer.

International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

G. Scagliotti, Keunchil Park, Y. Ichinose, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.

C. Gridelli, F. Hirsch, V. Georgoulias, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations

Federico Cappuzzo, Paul Delmar, Tudor Ciuleanu, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

D. Richel, T. Ciuleanu, S. Cascinu, 2017, BMC Cancer.

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

E. Van Cutsem, M. Moore, T. Ciuleanu, 2014, British Journal of Cancer.

Cardiomyopathies and Arrhythmias Induced by Cancer Therapies

I. Berindan‐Neagoe, T. Ciuleanu, Diana Gulei, 2020, Biomedicines.

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

G. Scagliotti, F. Shepherd, S. Novello, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC.

G. Giaccone, F. Cappuzzo, T. Ciuleanu, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

J. Hainsworth, T. Ciuleanu, V. Tzekova, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).

N. Girard, D. Planchard, T. Ciuleanu, 2022, Journal of Clinical Oncology.

Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study

Yi-long Wu, M. Krzakowski, T. Ciuleanu, 2008 .

Effectiveness and safety profile of ipilimumab therapy in previously treated patients with unresectable or metastatic melanoma - the Romanian Patient Access Program.

T. Ciuleanu, S. Curescu, C. Aldea, 2017, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.

T. Ciuleanu, D. Cernea, N. Todor, 2007, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.

M. Aapro, Robert E. Smith, T. Ciuleanu, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.

Tudor Ciuleanu, Jacek Jassem, R. Ramlau, 2006, Lung cancer.

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

C. Schumann, M. Socinski, R. Kurek, 2015, The Lancet. Oncology.

Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer

George Fountzilas, Tudor Ciuleanu, Thomas Zaraboukas, 2004, Medical oncology.

Novel cellular and molecular approaches to stratification and treatment of colorectal cancer.

I. Berindan‐Neagoe, T. Ciuleanu, O. Bălăcescu, 2012, Journal of gastrointestinal and liver diseases : JGLD.

Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial

A. Chella, C. Gridelli, V. Georgoulias, 2020, British Journal of Cancer.

Consensus on the medical treatment of colon cancer

W. Scheithauer, T. Gruenberger, J. Tabernero, 2008 .

PL03.09: Phase 3 Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, with Docetaxel versus Docetaxel in Advanced Non-Small Cell Lung Cancer (GALAXY-2)

R. Ramlau, S. Ramalingam, D. Fennell, 2017 .

Knowledge, attitudes and practices related to the COVID-19 outbreak among Romanian adults with cancer: a cross-sectional national survey

T. Ciuleanu, A. C. Bot, L. Mazilu, 2020, ESMO Open.

Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous Iron in patients with chemotherapy‐induced anemia

T. Ciuleanu, P. Silberstein, K. Bridges, 2010, American journal of hematology.

Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)

J. Hainsworth, T. Ciuleanu, V. Tzekova, 2008 .

Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

T. Ciuleanu, G. Bodoky, N. Tebbutt, 2012, Investigational New Drugs.

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

L. Urban, E. Felip, Han Chang, 2023, Journal for ImmunoTherapy of Cancer.

Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region

T. Ciuleanu, C. Szczylik, M. Mego, 2012, Expert opinion on pharmacotherapy.

A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers

P. Philip, J. Trojan, T. Ciuleanu, 2007, Investigational New Drugs.

Hypersensitivity reactions to platinum derivatives: findings of new predictive markers.

D. Leucuta, T. Ciuleanu, Anne-Marie Constantin, 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis by tumor epidermal growth factor receptor (EGFR) staining.

A. Santoro, T. Ciuleanu, P. Mainwaring, 2010 .

Cardiotoxicity Associated with Chemotherapy Used in Gastrointestinal Tumours

A. Buzoianu, T. Ciuleanu, D. Criṣan, 2021, Medicina.

Phase 3 study of palonosetron intravenous (IV) infusion versus IV bolus for chemotherapy-induced nausea and vomiting prophylaxis following highly emetogenic chemotherapy.

T. Ciuleanu, M. Karthaus, G. Rizzi, 2020, Journal of pain and symptom management.

Outcomes of patients with cancer infected with SARS-CoV-2: results from the Ion Chiricuţă Oncology Institute series

T. Ciuleanu, O. Bălăcescu, V. Briciu, 2022, ESMO Open.

Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial

F. de Marinis, G. Ceresoli, R. Ramlau, 2021, ESMO open.

Paclitaxel and carboplatin in relapsed or metastatic nasopharyngeal carcinoma: a multicenter phase II study.

T. Ciuleanu, G. Fountzilas, E. Ciuleanu, 2004, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

L. Urban, K. O'Byrne, S. Ramalingam, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic Non–Small Cell Lung Cancer in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

N. Reinmuth, Ying Cheng, E. Felip, 2022, Journal of Thoracic Oncology.

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.

D. Carbone, E. Felip, L. Paz-Ares, 2023, European journal of cancer.

LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis

K. O'Byrne, S. Ramalingam, M. Hellmann, 2019 .

4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status

K. O'Byrne, S. Ramalingam, M. Hellmann, 2021, Annals of Oncology.

Nivolumab Plus Low-Dose IPILIMUMAB as First-Line Treatment of Advanced NSCLC: Overall Survival Analysis of Checkmate 817

L. Urban, E. Felip, L. Paz-Ares, 2019 .

An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).

G. Scagliotti, Y. Ichinose, R. Pirker, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.

K. Syrigos, Keunchil Park, L. Paz-Ares, 2017, Lung cancer.

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.

N. Reinmuth, I. Horváth, K. Syrigos, 2022, The Lancet. Respiratory medicine.

A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.

A. V. Pavlovsky, T. Ciuleanu, G. Bodoky, 2009, European journal of cancer.

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

E. Van Cutsem, J. Tabernero, T. Ciuleanu, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.

T. Ciuleanu, F. Wrba, K. Kaczirek, 2015, Clinical colorectal cancer.

Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors?

T. Ciuleanu, E. Buzdugan, L. Stoicescu, 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small‐Cell Lung Cancer

C. Obasaju, M. Socinski, R. Ramlau, 2017, Clinical lung cancer.

Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.

J. Tabernero, Tae Won Kim, T. Ciuleanu, 2017, European journal of cancer.

Profiling immunohistochemical expression of NOTCH1–3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary

N. Pavlidis, T. Ciuleanu, G. Fountzilas, 2012, Clinical & Experimental Metastasis.

A. Bezjak, L. Seymour, S. Thongprasert, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.

K. O'Byrne, S. Ramalingam, M. Hellmann, 2020 .

Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC).

K. Syrigos, Keunchil Park, L. Paz-Ares, 2015 .

PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial

L. Paz-Ares, T. Ciuleanu, C. Grohé, 2021, Journal of Thoracic Oncology.

Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.

M. Socinski, G. Scagliotti, E. Smit, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

D. Richel, D. V. Von Hoff, T. Ciuleanu, 2017, BMC Cancer.

Clinical Outcomes, Treatment and Testing Patterns in Patients with Advanced Non-Small Lung Cell Cancer with Epidermal Growth Factor Receptor Mutations: Results of the Romanian Cohort From a Multi-national Retrospective Chart Review (REFLECT)

T. Ciuleanu, A. Alexandru, M. Dediu, 2022, Journal of Medical and Radiation Oncology.

Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT)

T. Ciuleanu, A. Płużański, M. Dediu, 2022, Current oncology.

Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)

A. Addeo, T. Ciuleanu, A. Płużański, 2021, Therapeutic advances in medical oncology.

Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.

T. Ciuleanu, S. Orlov, H. Breitz, 2010 .

First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 ≥ 1%: Patient-Reported Outcomes From CheckMate 227 Part 1.

K. Syrigos, K. O'Byrne, T. Ciuleanu, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.

D. Carbone, E. Felip, L. Paz-Ares, 2021 .

A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).

W. Guo, F. Khuri, E. Felip, 2013, Journal of Clinical Oncology.

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer Whose Tumors Harbor Uncommon Epidermal Growth Factor Receptors Mutations

F. Cappuzzo, T. Mok, O. Spleiss, 2016 .

Abstract CT178: Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study

H. Gómez, R. Cristescu, T. Ciuleanu, 2021, Clinical Trials.

Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2).

R. Ramlau, S. Ramalingam, D. Fennell, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

88PD EFFICACY AND SAFETY OF ERLOTINIB VERSUS CHEMOTHERAPY IN SECOND-LINE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH POOR PROGNOSIS: THE PHASE III TITAN STUDY

T. Ciuleanu, L. Stelmakh, S. Cicėnas, 2011 .

Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis.

S. Novello, M. Krzakowski, T. Ciuleanu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of palonosetron (PALO) given as 30-min IV infusion (IV inf) versus 30-sec IV bolus (IV bol) for prevention of chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy (HEC).

T. Ciuleanu, P. Szabo, M. Karthaus, 2017 .

Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non–Small-Cell Lung Cancer: A Lead-In Study

H. Groen, L. Tye, T. Ciuleanu, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

O-020Quality-of-life results from RAISE: randomized, double-blind phase III study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal carcinoma after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine

T. Ciuleanu, G. Bodoky, P. Rougier, 2015 .

Trabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studies

T. Ciuleanu, C. Sessa, N. Colombo, 2007 .

Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

P. Ascierto, M. Burotto, T. Ciuleanu, 2022, Cancer Research.

First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).

N. Reinmuth, Ying Cheng, T. John, 2023, Journal of Clinical Oncology.

Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: Preliminary results.

T. Ciuleanu, A. Poveda, M. Izquierdo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1

K. O'Byrne, M. Hellmann, H. Borghaei, 2021, Annals of Oncology.